2008
Authors: Gibb DM, Compagnucci A, Green H, Lallemant M, et al.
Published in: Journal of the International AIDS Society 2008, 11(Suppl 1):O21 (10 November 2008)
2008
Authors: Cressey TR, Green H, Khoo S, Treluyer J-M, Compagnucci A, Saidi Y, Lallement M, Gibb DM, Burger D.
Published in: Clin Infect Dis 2008. 15;46(10):1601-8
Background The optimum strategy for stopping treatment with drugs that have different half-lives in a combination regimen to minimize the risk of selecting drug-resistant viruses remains unknown. We evaluated drug concentrations in plasma,
2008
Authors: Dunn DT, Woodburn P, Duong T, Phillips AN, Gibb D, Porter K on behalf of HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) and the CASCADE Collaboration.
Published in: J Infect Dis 2008, 197:398-404
2008
Authors: Jacobsen MC, Thiebaut R, Fisher C, Sefe D, Clapson M, Klein NJ, Baxendale HE.
Published in: 5th Conference on Retroviruses and Opportunistic Infections, Boston, 2- 8 February 2008, Poster A-152 /453
2008
Authors: Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee
Published in: AIDS. 2008 Jan 2;22(1):97-105.
2007
Authors: Goetghebuer T for the European Infant Collaborative Study.
Published in: 4th Dominique Dormont International Conference, 13-15 December, 2007
2007
Published in: American Academy of Pediatrics, 2007; 119: 838-845
2007
Authors: Green H and Gibb DM.
Published in: Curr Opin HIV AIDS 2007; 2:62-68.
2007
Authors: Compagnucci A, Saïdi Y, Harper L, Blanche S, Gabiano C, de José Gomez I, Notheis G, Gibb DM, Giaquinto C and Faye A for the PENTA 7 committees
Published in: 14th Conference on Retroviruses and Opportunistic Infections, 25th-28th February 2007, Los Angeles. Poster 722 Abstract R -151
2007
Authors: Gibb DM, Green H, Saidi Y, et al; on behalf of PENTA 5.
Published in: AIDS.2007;21(8):947-955
Objective To describe the long-term efficacy over 5 years of regimens including combinations of abacavir, lamivudine and/or zidovudine in previously untreated children in the PENTA 5 trial.
Design PENTA 5 was a 48-week randomised controlled trial comparing three dual nucleoside reverse transcriptase inhibitor (NRTI) combinations as part of first triple antiretroviral therapy (ART).
2007
Authors: Dunn D, Woodburn P, Duong T, Phillips A, Gibb DM and Porter K on behalf of HPPMCS and CASCADE.
Published in: 14th Conference on Retroviruses and Opportunistic Infections, 25th-28th February 2007, Los Angeles. Poster 700
2006
Authors: Lallemant M, Burger D, Lyall H, Buck L, Compagnucci A, Ramos Amador J.T, Mellado Pena M, Fregonese F, Campbell S, Rampon O, Castelli-Gattinara G, Cressey, Khoo S, Tréluyer J.-M, Green H, Saidi Y, Nadal D, Giaquinto C, Gibb D.M on behalf of the PENTA 11 study group.
Published in: XVI International AIDS Conference, Toronto, 13-18 August 2006. Poster MOPE0206
2006
Authors: Babiker AG and Gibb DM.
Published in: Current Opinion in HIV and AIDS 2006; 1(6):488-494
2006
Authors: HIV Paediatric Prognostic Markers Collaborative Study.
Published in: AIDS 2006; 20:1289-1294
2006
Authors: LeProvost M, Green H, Flynn J, et al; on behalf of the PENTA 13 study group.
Published in: Pediatr Infect Dis J. 2006;25(6):533-7
Background Data on adherence to and acceptability of once daily lamivudine and abacavir are few.
Methods Twenty-four U.K. human immunodeficiency virus type-1 infected children 2-13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm,
2006
Authors: Aboulker J-P, Babiker A, Bacheler L, et al. On behalf of the PENTA 8 study group
Published in: Antivir Ther. 2006;11(7):857-867
Objective To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure.
Methods Children aged 3 months-18 years switching antiretroviral therapy (ART) with HIV-1 RNA >
2005
Authors: Urschel S, Ramos J, Mellado M, Giaquinto C, Verweel G, Schuster T, Niehues T, Belohradsky B, Wintergerst U; the European PCP-withdrawal Study Group.
Published in: AIDS. 2005 Dec 2;19(18):2103-2108.
2005
Authors: Giaquinto C, Green H, De Rossi A, et al. On behalf of the PENTA 8 study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Oral and poster presentation WeOa0106
Abstract The development of resistance to antiretroviral drugs is considered to be an important cause of treatment failure in HIV infection.
2005
Authors: LeProvost M, Green H, Flynn J, et al: on behalf of the PENTA 13 study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Poster MoPe9.2C03
2005
Authors: Compagnucci A, Saïdi Y, Gibb DM, Rampon O, Ramos Amador JT, Feiterna Sperling C, Reliquet V, Giaquinto C, Navarro ML, Girard S, Harper L, Burger D, Treluyer JM, Aboulker JP, Jacqz-Aigrain E and Faye A on behalf of the PENTA 7 Study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Abstract MoPe9.2C15
2005
Authors: HIV Paediatric Prognostic Markers Collaborative Study Group.
Published in: Lancet 2005; 366: 1868-74 .
2005
Authors: Bergshoeff A, Burger D, Verweij C, et al; on behalf of the PENTA 13 study group
Published in: Antivir Ther. 2005; 10:239-246
Background There are few data on plasma and intracellular pharmacokinetics (PK) of once-daily (q24h) nucleoside analogues in HIV-infected children.
Methods Children aged 2-13 years receiving combination treatment containing lamivudine (3TC) (4 mg/kg) and/or abacavir (ABC) (8 mg/kg) twice daily (q12h) were included in this single-arm,
2005
Authors: De Rossi A, Walker AS, De Forni D, Klein N, Dibb DM. Paediatric European Network for Treatment of AIDS (PENTA)
Published in: Antivir Ther. 2005;10(1):63-71
Objectives and Methods To investigate the relationship between cell-associated HIV-1 dynamics and recent thymic T-cell emigrants, HIV-1 DNA and T-cell receptor rearrangement excision circles (TREC, a marker of recent thymic emigrants) were measured in peripheral blood mononuclear cells in 181 samples from 33 HIV-1-infected children followed for 96 weeks after antiretroviral therapy(ART) initiation.
2004
Authors: Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saïdi Y, Ortiz AA, Toye M, Girard S, Mofenson L, Giaquinto C, Hughes M on behalf of the PENPACT 1 Trial.
Published in: XV International AIDS Conference, 11-16 July 2004, Bangkok. Poster TuPeB4442.
2004
Authors: Compagnucci A, Saïdi Y, Harper L, Navarro ML, Girard S, Walker AS, Debré M, Gibb DM, Rampon O, Lachassine E, Schmitz T, Giaquinto C, Aboulker JP, Fay
Published in: XV International AIDS Conference, 11-16 July 2004, Bangkok. Abstract B11956.
2004
Authors: Aboulker JP, Babiker A, Chaix ML, et al; Paediatric European Network for Treatment of AIDS.
Published in: AIDS. 2004.23;18(2):237-45
2004
Authors: Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM for the PENTA Steering Committee.
Published in: HIV Med 2004; 5, (Suppl. 2), 61-86
2004
Authors: Writing Committee (alphabetical): Aboulker J-P, Babiker A, Chaix ML, Compagnucci A, Darbyshire JH, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS
Published in: AIDS 2004;18 (2):237-245
Objective To assess the feasibility and impact of highly active antiretroviral therapy (HAART) started in vertically HIV-1-infected infants less than 3 months of age.
2004
Authors: Burger DM, Bergshoeff A, de Groot R, et al; on behalf of the PENTA 5 study group.
Published in: J Paediatr 2004;145(3):403-405
Abstract Differences in virologic response were compared in 32 HIV-infected children with a nelfinavir trough concentration either below (n=7) or above (n=25) 0.8 mg/L. Virologic response at week 48 was observed in 29% of children with subtherapeutic nelfinavir troughs versus 80% in children with therapeutic nelfinavir troughs (P=.02)
2004
Authors: Lanier ER, Givens N, Stone C, et al.
Published in: HIV Med. 2004;5(6):394-399
Objectives Abacavir (ABC) selects for four mutations (K65R, L74V, Y115F and M184V) in HIV‐1 reverse transcriptase (RT), both in vitro and during monotherapy in vivo. The aim of this analysis was to compare the selection of these and other nucleoside reverse transcriptase inhibitor (NRTI)‐associated mutations by ABC‐containing therapies in the presence and absence of concurrent lamivudine (3TC) and/or zidovudine (ZDV) and to assess the effect of these mutations on phenotypic susceptibility to the NRTIs.
2004
Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM.
Published in: 11th Conference of Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004. Poster 934.
2003
Authors: Compagnucci A, Saidi Y, Faye A, et al.
Published in: 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July Paris. Poster 1095
2003
Authors: HIV Paediatric Prognostic Markers Collaborative Study Group.
Published in: Lancet 2003; 362:1605-11.
2003
Authors: Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E for PENTA.
Published in: Pediatr Inf Dis J 2003; 22(1):48-55
Background In children younger than 2 years of age vertically infected with HIV-1, the recommended pediatric dosing regimen for nelfinavir (20 to 30 mg/kg three times a day) provides insufficient drug exposure.
2003
Authors: Gibb DM, Giaquinto C, Walker AS, Harper L, Compagnucci A, Saidi Y, Moulinier C, Aboulker JP, Babiker AG, Debré M, Darbyshire JH on behalf of the PENTA 5 Executive Committee
Published: 10th Conference on Retroviruses and Opportunistic Infections February 10th – 14th, 2003 – Boston. Poster G1-12
2003
Authors: De Rossi A, Walker AS, De Forni D, Gibb DM on behalf of PENTA.
Published in: 10th Conference on Retroviruses and Opportunistic Infections February 10th – 14th, 2003 – Boston. Poster P-17
2003
Author: Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Paediatric European Network for Treatment of AIDS Steering Committee.
Published in: Pediatr Infect Dis J. 2003;22(1):56-62
2002
Authors: Ait-Khaled M, Lanier R, Richards N, Stone C, Griffin P, Gibb DM, Walker AS, Craig C, Loeliger E, Tisdale M
Published in: 2002 International Meeting of the Institute of Human Virology, September 9th-13th, 2002, Baltimore
2002
Authors: Giacomet V, Gibb DM, Goodall R, McGee L, Walker AS, Giaquinto C.
Published in: XIV World AIDS Conference, 7th-12th July 2002, Barcelona, Spain. Poster TuPpB2050
2002
Authors: Gibb DM, Walker AS, Giaquinto C, Harper L, Compagnucci A, Saidi Y, Aboulker JP, Babiker A, Debré M, Darbyshire JH on behalf of the PENTA 5 Steering Committee.
Published in: XIV World AIDS Conference, July 7th-12th 2002, Barcelona, Spain- Poster TuPpB2051
2002
Authors: Sharland M, Castelli Gattinara G, Tomas Ramos J, Blanche S, Gibb DM for the PENTA Steering Committee.
Published in: HIV Med 2002; 3:215-226
2002
Authors: De Rossi A, Walker AS, De Forni D, Gibb DM; Paediatric European Network for Treatment of AIDS (PENTA).
Published in: AIDS. 2002;16(14):1961-1963
2002
Authors: Pillay D, Walker AS, Gibb DM, De Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A. for the PENTA Steering Committee.
Published in: J Infect Dis 2002; 186: 617-25
Abstract The association between virologic response and human immunodeficiency virus type 1 (HIV-1) subtype was investigated in 113 HIV-1-infected children randomly assigned to receive zidovudine plus lamivudine,
2002
Authors: Gibb DM, Walker AS, Kaye S, et al.
Published in: Antivir Ther. 2002;7(4):293-303
Purpose and Methods To describe the evolution of resistance to zidovudine (ZDV), lamivudine (3TC), abacavir (ABC) and nelfinavir (NFV), 113 previously untreated children in the PENTA 5 trial had resistance assayed at baseline, rebound and/or 24, 48, 72 weeks (VIRCO: phenotyping and genotyping with ‘Virtual Phenotype’
2002
Authors: De Rossi A, Walker AS, Klein N, De Forni D, King D, Gibb DM.
Published in: J Infect Dis 2002; 186:312-20
Abstract To investigate the thymic contribution to immune reconstitution during antiretroviral therapy (ART), T cell receptor gene rearrangement excision circles (TRECs) were measured in peripheral blood mononuclear cells (PBMC) and CD4 cells from 33 human immunodeficiencyvirus (HIV) type 1-infected children monitored for 96 weeks after ART initiation.
2002
Authors: Paediatric European Network for Treatment of AIDS (PENTA)
Published in: Lancet.2002;359(9308):733-740
Introduction Treatment options for children with HIV-1 are limited. We aimed to compare activity and safety of three dual-nucleoside analogue reverse-transcriptase inhibitor (NRTI) regimens with or without a protease inhibitor in previously untreated children with HIV-1.
Methods In our multicentre trial,
2002
Authors: Compagnucci A, Saidi Y, Chaix ML, et al.
Published in: 9th Conference on Retroviruses and Opportunistic Infections February 24-28, 2002 – Seattle. Poster 809 – W.
2002
Authors: De Rossi A, Klein N, Walker AS, De Forni D, Babiker A, King D, Gibb DM for the PENTA Group.
Published in: 9th Conference on Retroviruses and Opportunistic Infections, February 24th-28th , 2002 – Seattle. Poster 807-W.
2002
Authors: Pillay D, Gibb DM, Walker AS, De Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A for the PENTA Group.
Published in: 9th Conference on Retroviruses and Opportunistic Infections, February 24th-28th, 2002 – Seattle. Poster 813-W
2001
Authors: Litalien C, Faye A, Compagnucci A, Jacqz-Aigrain E.
Published in: Pediatric Academic Societies 2001 Annual Meeting, April 28th – May 1st 2001, Baltimore MD. Abstract 2609.